Orphalan: makeover for an old drug and new studies for Wilson disease

Dr. Omar Kamlin
Senior Medical Director, Orphalan
We not only invited top doctors and experts to our virtual conference, but also medical directors from the pharmaceutical companies supporting Wilson disease patients.
Orphalan sponsored the largest study of Wilson disease patients to date and found that their new form of trientine works as well as penicillamine in stable patients. Orphalan announced that it will conduct a trial of this drug, marketed in the US as Cuvrior, in children with Wilson disease which is an understudied population.
Orphalan also launched the REASON trial to test a possible new monitoring assay in Wilson disease patients.
Learn more about Orphalan’s important work here.